TABLE 3.

Changes in CAPCSI scores, and serum concentrations of cPLI, CRP, and cytokines on Day 3 (after the third treatment administration) when compared to Day 0 (before treatment administration) from the PP population of 35 client‐owned dogs with AP after 3 days of IV administration of 0.4 mg/kg fuzapladib or placebo.

	Fuzapladib‐treated group (n = 16)		Placebo‐treated group (n = 19)
Secondary endpoint	Median	Min, Max	Median	Min, Max	P‐values a , b
CAPCSI score	−1.5	−3.0, 0.0	0	−4.0, 2.0	.06
cPLI (μg/L)	−338	−5703, 2102	−758	−8080, 5388	.29
CRP (mg/L)	−2	−87, 43	−19	−191, 40	.75
IL‐2 (pg/mL)	−4.9	−102.5, 15.0	1.5	−27.7, 43.2	.31
IL‐6 (pg/mL)	−5.0	−286.1, 74.2	−3.4	−210.2, 81.7	.97
IL‐8 (pg/mL)	38.1	−5720, 2596	185.7	−2191, 6183	.87
IL‐10 (pg/mL)	0	−3.6, 96.6	0	0.0, 0.4	.52
TNF‐α (pg/mL)	−0.4	−24.6, 4.9	0.2	−5.5, 7.0	.68

Abbreviations: CAPCSI, canine acute pancreatitis clinical severity index; cPLI, canine pancreatic lipase immunoreactivity; CRP, C‐reactive protein; IL, interleukin; TNF‐α, tumor necrosis factor‐alpha.

^a P‐value for Day 0 derived from ANOVA including group as fixed effect and random effects of site and group‐by‐site interaction. LSM difference (95% CI) and P‐value for the change (Day 3 minus Day 0) derived by repeated measures ANCOVA, including group, day, and group‐by‐day as fixed effects, site and group‐by‐site as random effects, and Day 0 as a covariate using CS as covariance structure.

^b Indicates values were ranked before ANOVA/ANCOVA, if the p‐value of the Shapiro‐Wilk test of the residuals was ≤.01.